

The redesignation form consists of three parts:

Part I - Institutional Profile

Part II - Terms of Reference (TOR)

Part III – Workplan

This redesignation form below, together with the Terms and conditions for WHO collaborating centres will serve as the agreement between the proposed institution and WHO if the redesignation as WHO collaborating centre is approved by WHO. Completion and submission of the redesignation form, however, does not guarantee that the designation will be approved.

Folder eCC_00038360 is in stage Form Completion (Institution)

| | |
|---|----------------------------|
| Name of the University, Hospital, Research Institute, Academy or Ministry | |
| Iran University of Medical Sciences | |
| Name of the Division, Department, Unit, Section or Area | |
| School of Behavioural Sciences and Mental Health, Teheran Institute of Psychiatry | |
| City | CC Reference Number |
| Teheran | IRA-22 |
| Title | |
| WHO Collaborating Centre for Mental Health | |

Part I - Institutional Profile

The status of WHO CC is granted to an administrative unit of an institution (i.e. department, division or unit) and not to the institution as a whole in the vast majority of cases. For example, WHO CC status is granted to the Department of Microbiology of the University of ABC and not to the university itself. A WHO CC is not a legal entity. The legal entity is the proposed institution, i.e. the ministry, academy, university, established research institute or hospital, of a part thereof.

In the section entitled “sources of funding” some questions refer to the proposed terms of reference and activities included in the workplan of this proposal. Therefore please limit your responses to what is relevant in relation to the proposed terms of reference and activities included in the workplan.

However, when a question refers to the "proposed institution", please provide information on the legal entity as a whole (for example the University of ABC).

Address of the proposed institution

| | |
|---|---|
| 1.1 Street and number | No 1 Shahied Hemmat Highway, beside Milad Tower |
| 1.2 City | Teheran |
| 1.3 State/Region/Canton/Province | Teheran |
| 1.4 Postal Code | 1449614535 |
| 1.5 Country | IRA |
| 1.6 WHO Region | EMRO |
| 1.7 Phone | (98-21) 86702611 |



1.8 Fax

(98-21) 88622528

1.9 Web site

http://www.sbsmh.iums.ac.ir/

If you would like your institution to receive important news and other communications from WHO (unrelated to the work as a WHO CC) such as launching of new WHO campaigns, new WHO publications, etc, please indicate an email address.

Staff of the proposed institution

1.10 Name of the director of the institution as a whole

Dr. Mohammad Reza Pirmoradi

1.11 - Name and email of the proposed heads of the WHO collaborating centre (Please note this information will be listed in the public database)

| Salutation | First Name | Last Name | Email Address |
|------------|---------------|-----------|-------------------------|
| Dr. | Mohammad Reza | Pirmoradi | Pirmoradi.mr@iums.ac.ir |
| Salutation | First Name | Last Name | Email Address |
| Dr. | Sahar | Eshrati | eshrati.s@gmail.com |

1.12 Please list the names of professional who will work on the proposed terms of reference or activities of the workplan together with their professional qualifications (e.g. Dr John Smith MPH). Please do not include full resumes or biographies.

- Dr. Mohammadreza Pirmoradi,MD, Clinical Psychologist
- Dr. Seyed Kazem Malakouti, Psychiatrist
- Dr. Mohsen Roshanpajouh, Psychiatrist
- Dr. Mehrdad Khazemzadeh Atoofi, Clinical Psychologist
- Dr. Mojgan Lotfi, Clinical Psychologist
- Dr. Sahar Eshrati, Addiction Studies
- Dr. Ghazaleh Zargari nezhad, Clinical Psychologist
- Dr. Mojtaba Dehghan, Health Psychologist
- Dr. Masoumeh Bayat, Neuroscientist
- Dr. Raziye Sadat Hoseini, Geriatrician
- Dr. Ali Fazeli, Health Psychologist
- Dr. Fateme Veisi, Clinical Psychologist

Sources of funding

NOTE: Private-sector entities in this form refer to three categories: (i) business associations representing commercial enterprises, (ii) entities that are not at "arms' length" from their commercial sponsors, and (iii) partially or fully state-owned commercial enterprises that act like private-sector entities.

An entity that is "at arms' length" from another entity should meet the following three conditions: (i) to be financially and organizationally independent from the other entity, (ii) not to take instructions from the other entity, and (iii) not to be influenced or not reasonably perceived to be influenced in its decisions, activities, mandate and work by the other entity.

1.13 During the last two years, what percentage of the funding of the proposed institution was core funding? Core funding refers to funding that is received regularly from secure sources, as opposed to ad-hoc contributions.

over 75% regular (core) funding



1.14 Please provide a complete list of donors that provide funding for the proposed institution, such as private-sector organizations, philanthropic foundations, nongovernmental organizations, governments, inter-governmental organizations and members of the public. Please include the full names of all donors, but not the amount donated.

WHO, EMRO
WHO, Iran Office
Ministry of Health and Medical Education, Mental Health Office

1.15 Tobacco/arms-related disclosure statement .

Under the WHO Framework of Engagement with non-State Actors, WHO does not engage with the tobacco industry or non-State actors that work to further the interests of the tobacco industry. Moreover, WHO does not engage with the arms industry.

For the purposes of this statement: tobacco industry refers to any entity involved in the manufacture, sale or distribution of tobacco and related products, and any affiliate of such an entity; and arms industry refers to any entity involved in the manufacture, sale or distribution of arms, and any affiliate of such an entity.

To determine whether the proposed institution conforms to this rule, please answer the following questions:

- **Is the proposed institution, or was the proposed institution over the last four years, part of the tobacco or arms industries (as defined above)?**
- **Is the proposed institution, or has the proposed institution over the last four years, engaged in activities that support the interests of the tobacco industry? This includes, but is not limited to, supply contracts, contract work, services and lobbying.**
- **Does the proposed institution currently, or did the proposed institution over the last four years, have any other association or relationship with the tobacco industry (as defined above)? This includes in particular investment interests (other than general mutual funds or similar arrangements whereby the institution has no control over the selection of the investments), commercial business interests, the provision or receipt of financial and/or other support.**
- **Does the proposed institution have any formal association, affiliation or links with private-sector entities and other non-State actors whose policies or activities negatively affect human health and are not in line with WHO’s policies, norms and standards, in particular those related to noncommunicable diseases and their determinants?**

The answer is yes to at least one of the questions above. Please provide details

By selecting this choice I confirm that the answer to all the questions above is no

[If yes] Please provide details (i.e. the names of entities, their activities, level of funding).

1.16 Is there any prospect that the proposed terms of reference or activities of the workplan will be funded by one or more private-sector entities that have, or may be perceived as having, a direct or indirect commercial interest in those proposed terms of reference or activities of the workplan?

Yes No

[If yes] Please provide the names of these entities, their business activities and the level of funding.

1.17 Is any of the proposed terms of reference or activities of the workplan, or is there a prospect that any of the proposed terms of reference or activities of the workplan will be, performed as part of or related to work (research or other) commissioned by private-sector entities?

Yes No

[If yes] Please provide the names of these entities, their business activities and the level of funding.



1.18 Is any of the proposed terms of reference or activities of the workplan, or is there a prospect that any of the proposed terms of reference or activities of the workplan will be, funded directly or indirectly by unspecified funds from one or more private-sector entities?

Yes No

[If yes] Please provide the names of these entities, their business activities, level of funding, for what such funding is being, or will be, used and whether the implementation of the proposed terms of reference and activities of the workplan is dependent on the support of one or more of these private sector entities.

1.19 Are the salaries of staff who will work on the proposed terms of reference or activities of the workplan or their posts funded by one or more private sector entities, were they ever funded in this way in the past or could they receive such funding in future?

Yes No

[if yes] Please provide the names of these entities, their business activities, level of funding, for which staff or what posts such funding is being, or will be, used, and the functions of such staff and/or posts.

1.20 Did over the last three years, does currently, or is there a prospect that, any specific staff who will work on the proposed terms of reference or activities of the workplan (including the proposed head(s) of the WHO collaborating centre), have any other interactions, affiliations or relations with, or any other personal, professional, financial or business interests in, one or more private sector entities that could give rise to a real or perceived conflict of interest or reputational risk?

Such risks may exist

- (i) if the private sector entity has a direct or indirect commercial interest in all or part of the proposed terms of reference or activities of the workplan, or may be perceived as having such interest;**
- (ii) if the business activities of the entity engage with the tobacco industry and /or arms industry; or non-State actors that work to further the interests of the tobacco industry ; or**
- (iii) if the private sector entity has a vested interest in exerting influence on the proposed terms of reference or activities of the workplan and/or their outcome or may be seen as having such interest.**

Interactions, affiliations, relations with, or other personal, professional, financial or business interests include, but are not necessarily limited to, collaborative projects or initiatives, employment, consultancy, investment interests (e.g. stocks, bonds, stock options, other securities, but not mutual funds, pension funds or similar investments that are broadly diversified), commercial business interests (e.g., proprietorships, partnerships, joint ventures), patents, trademarks, or copyrights (including pending applications), proprietary know-how in a substance, technology or process.

Yes No

[if yes] Please provide details.

Institutional characteristics



1.21 What type of entity is the proposed institution?

Public

Please provide details

University

By ticking this box you confirm that the entity you represent is a nonprofit entity.

1.22 Please attach a current organizational chart (1 page) of the institution, including its administrative units such as divisions, departments, sections or areas (whichever structure applies), indicating the one proposed as WHO collaborating centre.

Flowchart.docx

1.23 Please attach the constitutive documents of the institution you represent e.g. constitution, registration document, by-laws or similar.

Constitutive documents of the institution in persian1.rar

1.24 Number of years the institution is in operation.

more than 10 years

1.25 Please list major facilities and any specialized equipment available to the proposed institution (e.g. laboratories, training facilities, documentation centre), if applicable. Please do not list general office space or standard office equipment.

1. Computer network laboratory
2. One-way mirror rooms

1.26 Does the proposed institution currently establish a smoke-free environment across its premises, which can be illustrated either through a documented institutional/departmental policy or through the existence of national/local smoke-free legislation? The smoke-free environment must apply to all indoor workplaces and public places of the institution's premises, and must entail a complete ban of smoking indoors and no areas designated for smoking.

No

I understand that information on my entity and its engagements with WHO that are categorized as public domain will be published in the WHO Register.

The proposed institution agrees with the following Terms and conditions for WHO collaborating centres.

Part II - Terms of Reference (TOR)

Please include the proposed terms of reference for the future collaboration between the proposed institution and WHO, as discussed prior to completing this form. In most cases, 1-3 TOR will be sufficient to provide a high-level framework of the future collaboration. For redesignations, the current terms of reference is automatically prefilled but can be revised as appropriate.

For detailed instructions on how to fill in this section please click on the link provided at the top of the form.

TOR 1 As per WHO's request and under its leadership, provide support to WHO in the translation, dissemination, implementation, adaptation and evaluation of WHO guidance documents in the areas of mental health specifically to support the integration of mental health into primary health care.



TOR 2 As requested by WHO, and under its leadership participate in activities enhancing mental health literacy to reduce stigma and promote mental health and prevent mental disorders including suicide.



Part III – Workplan

| | |
|-------------------------------------|--|
| <p>Activity ID 39243</p> | <p>Activity title Translation ,dissemination and implementation of WHO guidance documents in the areas of mental health and associated tools ,Instruments and training materials specifically to support the integration of mental health into primary health care.</p> <p>Link to TOR TOR1</p> <p>Name(s) of responsible staff at the institution Raziyeh Sadat Hoseini, Masoumeh Bayat,Mohammadreza Pirmoradi</p> <p>Type of activity Information dissemination</p> <p>Why WHO is asking for this activity and how WHO will use the deliverables? After updating of the mhGAP-IG the next step is the dissemination and implementation of mhGAP-IG V.03 at country level. It is in line with WHO’s plan to widely disseminate and implement evidence based guidance and tools to promote integration of mental health within PHC . This is required as a part of WHO strategic priority 1 (one billion more people benefiting from universal health coverage) and programmatic output 1.1.2 of GPW13 (Countries enabled to strengthen their health systems to deliver on condition- and disease-specific service coverage results). This is also aligned to the Global action plan for mental health 2013-2030 and the regional framework for scaling up action on mental .This will thus help WHO in reporting on the SDGs as well on the GPW 13 targets</p> <p>What concrete actions will be taken by the designated institution? Be specific. Upon request from WHO, the School of Behavioural Sciences and Mental Health, Teheran Institute of Psychiatry ,Iran university of Medical sciences will utilize standard WHO recommendation for translating the WHO guidance documents in the areas of mental health (mhGAP- IG) and associated tools ,Instruments and training materials in Persian language, and their dissemination</p> <p>What will be WHO’s role in this activity? WHO will lead the liaison with Member States and communicate requests from Member States as appropriate. WHO will review and approve all outputs related to this activity and ensure their alignment with WHO’s norms, rules, policies, and standards including the design and content of the capacity building. WHO will provide technical guidance to the institution at all stages of this activity including contacting and seeking approval from the</p> |
|-------------------------------------|--|



**Collaborating Centres
REDESIGNATION FORM**

| | |
|---------------------------------|--|
| | <p>WHO unit responsible for Clearing translations in other than official languages i.e. QNS/WHP .</p> <p>WHO may use the technical inputs developed by the entity on the subject matter as deemed appropriate.</p> <p>Expected deliverables</p> <p>1) Persian translation of WHO guidance documents in the areas of mental health (mhGAP- IG) and associated tools ,Instruments and training materials 2) Persian version of screening and diagnostic instruments for scaling up integration of mental health in PHC 3) Institution's participation in WHO-fora for scaling up mhGAP dissemination and implementation</p> <p>Intellectual property rights</p> <p>IP rights of ALL deliverables belong to WHO as per paragraphs 3.1.2 and/or 3.2.2 of the Terms and Conditions</p> <p>Name(s) of funding sources</p> <p>Institution's budget Subject to availability of funds,</p> <p>Activity timeframe</p> <p>June 2024- June 2028</p> <p>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</p> |
| <p>Activity ID 39244</p> | <p>Activity title</p> <p>scaling up the capacity of general health care personnel to deliver basic mental health services and intervention in line with the mhGAP initiative of WHO.</p> <p>Link to TOR</p> <p>TOR1</p> <p>Name(s) of responsible staff at the institution</p> <p>Mohsen Roshanpajouh, Sahar Eshrati</p> <p>Type of activity</p> <p>Support WHO in the implementation of WHO programmes and activities at country level</p> <p>Why WHO is asking for this activity and how WHO will use the deliverables?</p> <p>After updating of the mhGAP guidelines the next step is the dissemination and implementation of mhGAP-IG V.03 at country level. It is in line with WHO's plan to widely disseminate and implement evidence based guidance and tools to promote integration of mental health within PHC .</p> <p>This is required as a part of WHO strategic priority 1 (one billion more people benefiting from universal health coverage) and programmatic output 1.1.2 of GPW13 (Countries enabled to strengthen their health systems to deliver on condition- and disease-specific service coverage results).</p> |



Collaborating Centres REDESIGNATION FORM

| | | |
|---------------------------------|---|---|
| | <p>What concrete actions will be taken by the designated institution? Be specific.</p> <p>What will be WHO's role in this activity?</p> <p>Expected deliverables</p> <p>Intellectual property rights</p> <p>Name(s) of funding sources</p> <p>Activity timeframe</p> <p>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</p> | <p>This is also aligned to the Global action plan for mental health 2013-2030 and the regional framework for scaling up action on mental .This will thus help WHO in reporting on the SDGs as well on the GPW 13 targets</p> <p>At WHO's request, the institution would conduct training of trainers and supervisors , in line with WHO's norms, standards and policies. Each such meeting would invite minimum 20 participants annually from the region to train mental health professionals, using mhGAP-IG , and associated training packages to promote integration of mental health in PHC.</p> <p>WHO will lead the liaison with Member States and communicate requests from Member States as appropriate. WHO will review and approve all outputs related to this activity and ensure their alignment with WHO's norms, rules, policies, and standards including the design and content of the capacity building. WHO will provide technical guidance to the institution at all stages of this activity. WHO may use the technical inputs developed by the entity on the subject matter as deemed appropriate.</p> <p>At least one TOT is conducted annually with 20 participants from the member states participating in each . Report on ToT's conducted and scaling up the capacity of PHC personnel and FPs for early recognition and management of priority mental disorders in Member States</p> <p>IP rights of ALL deliverables belong to WHO as per paragraphs 3.1.2 and/or 3.2.2 of the Terms and Conditions</p> <p>Institutional budget. Subject to availability of funds,</p> <p>December 2024 -April 2028</p> |
| <p>Activity ID 39245</p> | <p>Activity title</p> <p>development of technical product describing models of care for integrated delivery of services for people with Mental Health conditions across continuum of care.</p> | |



| | |
|--|--|
| Link to TOR | TOR1 |
| Name(s) of responsible staff at the institution | Mehrddad Khazemzadeh Atoofi, Mojgan Lotfi |
| Type of activity | Product development (guidelines; manual; methodologies; etc.) |
| Why WHO is asking for this activity and how WHO will use the deliverables? | <p>As a part of WHO strategic priority 1 (one billion more people benefiting from universal health coverage) and programmatic output 1.1.2 of GPW13 (Countries enabled to strengthen their health systems to implement condition- and disease-specific programmes), WHO provides normative guidance and support to countries with guidance and tools for improving services for people with substance use disorders. In line with the priority, WHO recently updated mhGAP Guidelines (2023) for mental, neurological and substance use disorders in non-specialized health settings, and started its implementation in countries of different regions.</p> <p>Iran has rich experience in integrating interventions on mental health and substance use disorders in the PHC and provision of a variety of services and settings for treatment of substance use disorders. It is well positioned to describe nuances of models of care for integrated delivery of services for people with substance use disorders across continuum of care, to facilitate implementation of WHO mhGAP guidelines. This activity is in line with WHO's aims in reducing global barriers to the effective treatment and improving the quality of treatment of drug use disorders, and will contribute to the WHO global good on integrated technical packages for identification and management of disorders due to substance use and addictive behaviours.</p> |
| What concrete actions will be taken by the designated institution? Be specific. | <p>Upon request from WHO, The Institution will participate in the development of MH GAP Intervention Guide 3.0 and assist WHO/EMRO in preparing description of models of care for mental health conditions , including a case-study on integrated delivery of services in the primary health care.</p> |
| What will be WHO's role in this activity? | <p>(i) WHO will review and approve all outputs related to this activity and ensure their alignment with WHO's norms, rules, policies, and standards including the content of technical product.</p> <p>(ii) Review draft documents and lead discussions on its revision and finalization; WHO will provide technical guidance to the institution at all stages of this activity.</p> |



| | |
|---------------------------------|--|
| | <p>Expected deliverables</p> <p>1) Submit suggestion on the implementation of mhGAP Guidelines (2023) for mental, neurological and substance use disorders in non-specialized health settings in EMRO region 2) at least one Literature review on model of mental health care delivery as requested by WHO, 3) Case-study on integrated delivery of services in the primary health care,</p> <p>Intellectual property rights</p> <p>IP rights of ALL deliverables belong to WHO as per paragraphs 3.1.2 and/or 3.2.2 of the Terms and Conditions</p> <p>Name(s) of funding sources</p> <p>Regular institutional budget</p> <p>Activity timeframe</p> <p>Deliverable 1 - end of 2024 Deliverable 2 - 2025-26 Deliverable 3 – 2027-2028</p> <p>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</p> |
| <p>Activity ID 39246</p> | <p>Activity title</p> <p>Dissemination, and implementation of interventions to reduce stigma associated with mental health and minimize discrimination faced by persons with mental health conditions</p> <p>Link to TOR</p> <p>TOR2</p> <p>Name(s) of responsible staff at the institution</p> <p>Mojtaba Dehghan, Ali Fazeli, Mohammadreza Pirmoradi</p> <p>Type of activity</p> <p>Support WHO in the implementation of WHO programmes and activities at country level</p> <p>Why WHO is asking for this activity and how WHO will use the deliverables?</p> <p>Stigma is an overarching problem with its attendant discrimination contributes to perpetuation of outdated models of care, minimal allocation of resources for mental health and human right abuses. The result is a massive treatment gap for mental health problems despite availability of cost effective and affordable interventions. This activity will be supporting WHO in development/implementation of the regional initiatives to address the issue of stigma and discrimination in countries of the region. This activity is in line with WHO's aims in reducing global barriers to the effective treatment and improving the quality of treatment, contributing to the GPW13 program output 1.1.2: Countries enabled to strengthen their health systems to deliver on condition- and disease-specific service coverage results.</p> |



| | |
|---------------------------------|---|
| | <p>What concrete actions will be taken by the designated institution? Be specific.</p> <p>At the request of WHO and under its guidance the institute will: 1) Conduct at least 02 trainings using the WHO Quality and Rights toolkit to enhance capacities of professionals and Civil society members to assess the quality of mental health services in facilities and institutions delivering Mental health care services. 2) Develop at least 02 videos of persons with Lived experience (PWLE) sharing their experience of challenges faced due to their mental health conditions and the steps they took to overcome the challenges and barriers to care</p> <p>What will be WHO's role in this activity?</p> <ul style="list-style-type: none"> • WHO will review and approve all outputs related to this activity and ensure their alignment with WHO's norms, rules, policies, and standards. • WHO will provide technical and expert guidance including relevant documents to the institution at all stages of this activity. • WHO will solely liaise with Member States. • WHO will disseminate the outcomes of the activity to the relevant stakeholders as appropriate. <p>Expected deliverables</p> <p>1) Report(s) of the trainings conducted using the Q&R tools 2) Video(s) of PWLE disseminated on WHO website</p> <p>Intellectual property rights</p> <p>IP rights of ALL deliverables belong to WHO as per paragraphs 3.1.2 and/or 3.2.2 of the Terms and Conditions</p> <p>Name(s) of funding sources</p> <p>Institutional Budget .</p> <p>Activity timeframe</p> <p>2025-27 for deliverable 1 2025 for deliverable 2</p> <p>This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.</p> |
| <p>Activity ID 39247</p> | <p>Activity title</p> <p>support development of technology platform (S) for suicide prevention</p> <p>Link to TOR</p> <p>TOR2</p> <p>Name(s) of responsible staff at the institution</p> <p>Fatemeh Veisi, Ghazaleh Zargari nezhad, RaziyeH Sadat Hoseini, Seyed Kazem Malakouti</p> <p>Type of activity</p> <p>Development and application of appropriate technology</p> <p>Reduction in Suicide rates is one of the core indicators related to mental health both in</p> |



Why WHO is asking for this activity and how WHO will use the deliverables?

GPW 13 and Global action plan for mental health in addition to being an indicator related to 3.4.1 SDG target.WHO will be able to benefit from this development to scale up Suicide prevention activities and overcome the socio cultural barriers.
This is required as a part of WHO strategic priority 1 (one billion more people benefiting from universal health coverage) and programmatic output 1.1.2 of GPW13 (Countries enabled to strengthen their health systems to deliver on condition- and disease-specific service coverage results).

What concrete actions will be taken by the designated institution? Be specific.

The institution would As requested by WHO, develop an e-health technology platform for suicide prevention which can be used by Farsi language countries like Afghanistan and Tajikistan in the short term and support the adaptation of the platform for use in other countries . The institution will also translate and support the dissemination of the WHO tool for monitoring responsible media reporting of Suicidal behaviours

What will be WHO’s role in this activity?

WHO will provide technical support and guidance to ensure that the content is technically sound and that all internal applicable norms, standards and policies are respected. WHO will solely liaise with Member States. WHO will disseminate the product to the relevant stakeholders as appropriate. WHO may use the technical inputs developed on the subject matter as deemed appropriate.

Expected deliverables

1) Development of suicide prevention intervention(s) platform which will be managed by the WHOcc but the content will need to be co developed and cleared by WHO to ensure that the content is technically sound and that all internal applicable norms, standards and policies are respected
2)Submit to WHO Farsi translated tool for monitoring responsible media reporting of Suicidal behaviours and WHO will provide technical guidance to the institution at all stages of this activity including approval from the WHO unit responsible for Clearing translations in other than official languages i.e. QNS/WHP

Intellectual property rights

IP rights of ALL deliverables belong to WHO as per paragraphs 3.1.2 and/or 3.2.2 of the Terms and Conditions

Name(s) of funding sources

Institutional Budget .

Activity timeframe

2025 for deliverable 1



**World Health
Organization**

Collaborating Centres REDESIGNATION FORM

And 2025-27 for deliverable 2

This activity has been specifically developed for the workplan of the WHO collaborating centre and does not constitute a standard activity of the institution without WHO involvement.